For AML with FLT3 mutation, small molecule tyrosine kinase inhibitors such as sorafenib, midostaurin and sunitinib have been available for the inhibition of the FLT3 signaling pathway and for the targeted killing of leukemia cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.